Lumos Diagnostics (ASX: LDX) (OTCPK: LDXHF) shares are up 500% today. LDX stock is up as a result of the FDA authorising their FebriDx test for use in the United States. Yes, this is important news, this will make a difference to the company. But 500%? It is possible to think that that might be a little bit of an over-reaction.
The announcement itself: “ Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a
leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received clearance from the US Food and Drug Administration (FDA) to market its FebriDx® rapid, point-of-care test in the United States.” The test enables the medics to differentiate between viral and bacterial infections. This matters because CDC - and everyone else - would like to reduce antibiotic use, antibiotics only work on bacterial infections, so distinguishing the - more common - viral infections will be useful.
It's also true that pretty much nothing can be sold into the US medical market without FDA approval - certainly not diagnostics tests. So, this does open up the world's largest and richest market to the company. It's important.

Lumos Diagnostics share price from ASX
On the other hand we can also consider this - the test is already authorised in a number of countries: “FebriDx is already registered in the UK, Europe, Canada, UAE, Brazil, Turkey, Pakistan, Singapore, Malaysia and Australia” In total that's rather larger than the US market. Even if we restrict ourselves to rich world the EU alone is about the same size (more people, less rich). So will sales boom in this new market?
There's even a third way of thinking about this. When already approved in much of the rich world this FebriDx test made Lumos Diagnostics worth about $4 million - and that's in the smaller, bijou, Australian dollars. Doubling the size of the population that can be addressed (the US is 330 million people, the EU 450 million, that's close enough for us here) is worth 500% on the LDX share price? Against this we should balance the other look at this, which is that is the Ameri can market worth $16 million in capital value?
We would probably say that perhaps it isn't worth 500% - given that it is legal to sell already in much of the rich world. On the other hand yes, the Americans use more diagnostics tests than anyone else, by a long, long, shot and it might well be worth that $16 million. So the valuation is all a bit swings and roundabouts really.
Our opinion, and it is merely opinion, is that the Lumos Diagnostics share price has got a bit ahead of itself here. Yes, FDA authorisation does normally mean a great deal to a pharma or medical testing company. But it's also usually the first authorisation received. So we'd expect LDX to possibly fade a bit as this all gets digested by the market. Yes, FDA approval is important, but 500% important for something already on sale to potentially half a billion people? We're unsure about that.